Found 690 clinical trials
Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy
This trial is designed to assess the efficacy of a novel carbon-fibre adjustable reusable accessory (CARA) for breast support to reduce skin toxicity and unwanted normal tissue dose in comparison to the current clinical standard for supine breast support during whole breast RT.
- 0 views
- 19 Feb, 2024
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.
This is a Phase II, open-label, randomized controlled umbrella trial evaluating the efficacy and safety of multiple targeted treatment in patients with metastaticTNBC.
- 0 views
- 19 Feb, 2024
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
To evaluate the efficacy,safety and immunogenicity of TQ-B211 plus docetaxel versus Herceptin plus docetaxel in Patients with HER2-positive metastatic breast cancer.Trastuzumab plus docetaxel was chosen as the comparator in the control group,as it represents a common first-line treatment option used in HER2+ MBC population in China.
- 0 views
- 19 Feb, 2024
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE
This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.
- 0 views
- 19 Feb, 2024
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC (PROPHET)
The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC. The main questions it aims to answer are:Does ctDNA clearance indicate pathological complete response?Are additional cycles of immunochemotherapy necessary for …
- 0 views
- 19 May, 2025
A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma
The worldwide collaboration is referred to as GLOBAL BALLAD and consists of a number of individual parallel prospective studies addressing the same objectives with similar designs brought together under the framework of the International Rare Cancer Initiative. This protocol is for BALLAD BELGIUM, which is the component of GLOBAL BALLAD.
- 0 views
- 19 Feb, 2024
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The information learned from this study will help researchers to learn more about the anti-myeloma activity of leflunomide, and whether it may delay the onset of …
- 0 views
- 19 Feb, 2024
PHP and Immunotherapy in Metastasized UM
Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs.
- 0 views
- 19 Feb, 2024
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)
This study is to find out what effects, both good and bad, this drug combination can have on you and to see if the study drug (SurVaxM) can create an immune response in your blood that is directed against cancer cells. This study also aims to find out if treatment …
- 0 views
- 02 Dec, 2024
- 10 locations
1 march 4
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
- 1 location